<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05116826</url>
  </required_header>
  <id_info>
    <org_study_id>NTZ-121-1</org_study_id>
    <nct_id>NCT05116826</nct_id>
  </id_info>
  <brief_title>Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients</brief_title>
  <official_title>An Open-label, Phase 1, Multiple-dose Study to Evaluate the Pharmacokinetics of Nitazoxanide 500 mg Twice Daily for 7 Days in Adult Subjects With Moderate and Severe Hepatic Impairment and Adult Healthy Control Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genfit</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genfit</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in&#xD;
      adult participants with hepatic impairment and healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to assess the effect of hepatic impairment on the&#xD;
      pharmacokinetics of the major Nitazoxanide active metabolite in hepatic impaired (moderate&#xD;
      and severe according to Child-Pugh categories) and healthy control adults following repeated&#xD;
      oral dose administration of NTZ 500 mg twice a day for 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve (AUC) from time zero to 12h (AUC0-12)</measure>
    <time_frame>Day 1: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10 and 12 hours post dose Day 7: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10; 12; 14; 16; 18; 24; and 48 hours post dose</time_frame>
    <description>In participants with moderate and severe hepatic impairment compared to healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time zero to the time of the last quantifiable concentration (AUC0-t)</measure>
    <time_frame>Day 1: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10 and 12 hours post dose Day 7: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10; 12; 14; 16; 18; 24; and 48 hours post dose</time_frame>
    <description>In participants with moderate and severe hepatic impairment compared to healthy volunteers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax),</measure>
    <time_frame>Day 1: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10 and 12 hours post dose Day 7: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10; 12; 14; 16; 18; 24; and 48 hours post dose</time_frame>
    <description>In participants with moderate and severe hepatic impairment compared to healthy volunteers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: time of the maximum observed plasma concentration (Tmax), apparent plasma terminal elimination half life (t1/2), AUC from time zero to infinity (AUC0-∞), trough concentration (Ctrough) and percentage of extrapolated (%AUCextrap)</measure>
    <time_frame>Day 1: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10 and 12 hours post dose Day 7: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10; 12; 14; 16; 18; 24; and 48 hours post dose</time_frame>
    <description>For NTZ and its major active metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma pharmacokinetics: Tmax, AUC0-12, AUC0-t, AUC0-∞, Cmax, t1/2, %AUCextrap and Ctrough.</measure>
    <time_frame>Day 1: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10 and 12 hours post dose Day 7: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10; 12; 14; 16; 18; 24; and 48 hours post dose</time_frame>
    <description>For the NTZ major active metabolite</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine pharmacokinetics: amount of drug excreted (Ae), cumulative amount of drug excreted (Ae0-t), and renal clearance (CLR)</measure>
    <time_frame>Day-1: pre-dose, Day 1: 0-4 h, 4-8 h, 8-12, 12-24 h post-dose; Day 7: 0-4 h, 4-8 h, 8-12 h, 12-24 h, 24-48 h post-dose</time_frame>
    <description>For the NTZ major active metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine pharmacokinetics: After the single oral administration of NTZ 500 mg: Cmax, AUC0-12, AUC0-t, AUC0-∞ , Tmax, t1/2, %AUCextrap, Ae0-∞, Ae0-t and CLR.</measure>
    <time_frame>Plasma:Day 1: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10, 12 h post dose Day 7: pre-dose; 1; 2; 3; 4; 5; 6; 7; 8; 10; 12; 14; 16; 18; 24; and 48 h post dose Urine:Day-1: pre-dose, Day 1: 24 hours urine collection post-dose; Day 7: 48 hours urine collection</time_frame>
    <description>For the NTZ major active metabolites</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Moderate Hepatic Impairment</condition>
  <condition>Severe Hepatic Impairment</condition>
  <condition>Liver Diseases</condition>
  <arm_group>
    <arm_group_label>Healthy Control Match (Normal hepatic function)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NTZ 500 mg twice a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Child-Pugh B (Moderate hepatic impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NTZ 500 mg twice a day for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Child-Pugh C (Severe hepatic impairment)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NTZ 500 mg twice a day for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>500 mg Twice Daily for 7 days</description>
    <arm_group_label>Healthy Control Match (Normal hepatic function)</arm_group_label>
    <arm_group_label>Moderate Child-Pugh B (Moderate hepatic impairment)</arm_group_label>
    <arm_group_label>Severe Child-Pugh C (Severe hepatic impairment)</arm_group_label>
    <other_name>NTZ</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, between 18 and 75 years of age, inclusive;&#xD;
&#xD;
          2. With a minimum body weight of 50 kg and within a BMI range of 18.0 to 40.0 kg/m^2,&#xD;
             inclusive;&#xD;
&#xD;
          3. Females participating in this study must be of non-childbearing potential or must be&#xD;
             using highly effective contraception for the full duration of the study;&#xD;
&#xD;
          4. Negative human immunodeficiency virus antibody screens at Screening;&#xD;
&#xD;
          5. Matched to participants with moderate and/or severe hepatic impairment in age (± 10&#xD;
             years), BMI (± 20 percentage) and sex;&#xD;
&#xD;
          6. Participants who have chronic (≥ 6 months) moderate or severe hepatic insufficiency&#xD;
             (of any etiology) that has been clinically stable (no acute episodes of illness due to&#xD;
             deterioration in hepatic function) for at least 1 month prior to Screening and must&#xD;
             also remain stable throughout the Screening period.&#xD;
&#xD;
        Other protocol-defined inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. A positive alcohol test result at Check-In Visit;&#xD;
&#xD;
          2. A history of alcohol abuse in the prior 2 years;&#xD;
&#xD;
          3. Positive urine screen for drugs of abuse at Screening or Check-In;&#xD;
&#xD;
          4. Strenuous exercise within 72 hours prior to Check-In Visit;&#xD;
&#xD;
          5. Blood donation or loss of blood (excluding volume drawn at screening or menses) of 50&#xD;
             mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the&#xD;
             dosing;&#xD;
&#xD;
          6. History of a major surgical procedure within 30 days prior to Screening;&#xD;
&#xD;
          7. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs except that appendectomy and&#xD;
             hernia repair will be allowed. Bariatric surgery will not be allowed;&#xD;
&#xD;
          8. Presence or history of malignancy within the prior 3 years, with the exception of&#xD;
             treated basal cell or squamous cell carcinoma;&#xD;
&#xD;
          9. Poor peripheral venous access;&#xD;
&#xD;
         10. Receipt of blood products within 2 months prior to Check-In Visit;&#xD;
&#xD;
         11. Significant history or clinical manifestation of any metabolic (including thyroid),&#xD;
             allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular&#xD;
             (including any prior history of cardiomyopathy or cardiac failure), gastrointestinal&#xD;
             (GI), neurological, or psychiatric disorder;&#xD;
&#xD;
         12. Positive serologic test for hepatitis B surface antigen or for hepatitis C virus&#xD;
             antibody at Screening;&#xD;
&#xD;
         13. Frequent headaches (&gt; twice a month) and/or migraines, recurrent nausea and/or&#xD;
             vomiting, diarrhea;&#xD;
&#xD;
         14. Participants with symptomatic hypotension at Screening, whatever the decrease of blood&#xD;
             pressure, or asymptomatic postural hypotension;&#xD;
&#xD;
         15. History of unstable diabetes mellitus;&#xD;
&#xD;
         16. Participants who have a transjugular intrahepatic portosystemic shunt and/or have&#xD;
             undergone portacaval shunting;&#xD;
&#xD;
         17. Participant has shown evidence of hepatorenal syndrome or has creatinine clearance ≤&#xD;
             60 mL/min;&#xD;
&#xD;
         18. Participants has required treatment for GI bleeding within the 6 months prior to&#xD;
             Check-In Visit;&#xD;
&#xD;
         19. Recent history of paracentesis (&lt; 1 months prior to Check-In Visit);&#xD;
&#xD;
         20. Participants with Wilson's disease, alpha-1 antitrypsin deficiency, glycogen storage&#xD;
             diseases, or galactosemia;&#xD;
&#xD;
         21. Participants with anemia secondary to hepatic disease, unless hemoglobin is ≥ 8.5 g/dL&#xD;
             and anemia symptoms are not clinically significant. Participants must have ≥ 30,000&#xD;
             platelets at screening and at Check-In Visit.&#xD;
&#xD;
        Other protocol-defined exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carol Addy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Genfit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genfit</last_name>
    <phone>+33 32 0164000</phone>
    <email>clinicaltrial@genfit.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2021</study_first_submitted>
  <study_first_submitted_qc>November 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>Liver Disease</keyword>
  <keyword>Hepatic Impairment</keyword>
  <keyword>Antiparasitic</keyword>
  <keyword>Antiprotozoal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

